Concert Pharmaceuticals, Inc.
Deuterated baricitinib

Abstract:

The present invention in one embodiment provides a compound of Formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification, as well as pharmaceutical compositions comprising the same, and methods of using such compounds and compositions to inhibit at least one of Janus Kinase-1 and -2 and diseases associated with those kinases.